A two-amino-acid peptide from Soviet-era bioregulation science—with mouse lifespan data, chromatin remodeling evidence, and no controlled human trial to its name.

Vilon is the simplest molecule in the Khavinson bioregulator family—two amino acids, lysine and glutamic acid, joined in a dipeptide bond. It weighs approximately 275 daltons, making it one of the smallest bioactive peptides on record. And yet, according to its developers, this two-amino-acid molecule can enter cell nuclei, interact with DNA, and selectively modulate immune gene expression.

That claim sits at the center of a 50-year research program conducted almost entirely within one institutional network: the St. Petersburg Institute of Bioregulation and Gerontology, founded and directed by Vladimir Khavinson until his death in January 2024. The program produced 775 publications, 196 patents, six approved pharmaceuticals in Russia, and a theoretical framework—"peptide bioregulation"—that proposes ultrashort peptides as natural gene regulators.

Vilon's preclinical data is more diverse than most compounds in this family. Mouse lifespan studies show extension and tumor inhibition. Ex vivo studies show chromatin remodeling in aged human lymphocytes. In vitro work shows cytokine modulation. The data tells a consistent story—but that story has been told almost exclusively by one lab, published primarily in Russian-language journals, and never subjected to independent replication or Western regulatory review.

For readers coming from the GLP-1 or BPC-157 evidence landscapes, Cluster S requires a different kind of evaluation. The question is not "does this compound have enough human data?" The question is "does this entire research paradigm hold up?"

Quick Facts: Vilon at a Glance

What Is Vilon?

Pronunciation: VY-lon

Vilon is a synthetic dipeptide—a molecule made of exactly two amino acids, L-lysine and L-glutamic acid, joined by a single peptide bond. Its molecular weight is approximately 275 Da, making it one of the smallest peptides studied for biological activity. For comparison, BPC-157 contains 15 amino acids and weighs ~1419 Da. Semaglutide contains 31 amino acids and weighs ~4114 Da. Vilon is an order of magnitude smaller.

It belongs to a family of compounds called "Khavinson bioregulators"—ultrashort peptides (2–7 amino acids) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The family includes nine synthetic compounds in Peptidings Cluster S, plus several others covered elsewhere on this site (Epitalon and Pinealon in Cluster C).

The bioregulator paradigm proposes that these ultrashort peptides are not traditional receptor agonists. They do not bind G-protein-coupled receptors, ion channels, or cytokine receptors in the way that most Western-developed peptide drugs work. Instead, they are proposed to enter cells, cross nuclear membranes, interact directly with DNA and histone proteins, and modulate gene expression in an organ-specific manner.

Vilon is the immune system's designated bioregulator in this framework—theorized to target thymic gene expression and restore immune function that declines with age.

Origins and Discovery

The story of Vilon begins in 1973, inside the Soviet military medical system.

Vladimir Khavinson, then a young military physician, was tasked with finding ways to restore immune function in soldiers exposed to high-dose radiation. The approach: extract peptide complexes from animal organs—initially calf thymus—and test whether these extracts could restore immune markers in irradiated subjects. The first extract was Thymalin, a complex mixture of thymic peptides that became one of six approved pharmaceuticals in Russia.

Over the following decades, Khavinson's team worked to identify the specific short peptides within these complex extracts that were responsible for the observed effects. This reductionist program produced Vilon—a synthetic dipeptide (Lys-Glu) identified as a minimal active sequence from the thymic peptide repertoire.

The research was classified until the Soviet Union's collapse in 1991. After declassification, Khavinson established the St. Petersburg Institute of Bioregulation and Gerontology and published prolifically—775 papers and 196 patents over the next three decades. Vilon appeared in numerous publications as both a standalone research subject and a tool for studying the broader bioregulator paradigm.

Khavinson died on January 6, 2024, at age 77. The future of the research program—and the question of whether independent labs will validate its core claims—remains open.

Mechanism of Action

Vilon's proposed mechanism is fundamentally different from most peptides on Peptidings. It does not work through receptor agonism.

The Bioregulation Hypothesis

According to the Khavinson paradigm, Vilon (Lys-Glu) enters cells and crosses the nuclear membrane due to its extremely small size (~275 Da). Once inside the nucleus, it is proposed to:

1. Interact with DNA — specifically with promoter regions of genes involved in immune function 2. Bind histone proteins — modifying chromatin structure 3. Decondense heterochromatin — converting tightly packed, transcriptionally silent DNA (heterochromatin) back into open, active DNA (euchromatin) 4. Reactivate age-silenced genes — restoring expression of immune-related genes that become progressively silenced with aging

This process is sometimes called "deheterochromatinization"—the reversal of the chromatin condensation that accumulates with age.

What the Published Data Shows

Ex vivo studies using lymphocytes from elderly donors report that Vilon treatment increased the proportion of transcriptionally active euchromatin, activated nucleolar organizer regions (sites of ribosomal RNA synthesis), and increased IL-2 gene expression. In the THP-1 monocyte/macrophage cell line (PMC 8999041, 2022), Vilon regulated proliferative activity and modulated inflammatory pathways.

The Specificity Question

This is the central mechanistic challenge for Vilon and all Khavinson bioregulators. A dipeptide of two of the most common amino acids in biology—lysine and glutamic acid—is proposed to achieve specific gene regulation. The Lys-Glu sequence appears in thousands of proteins throughout the human body. How does a free dipeptide of this sequence achieve targeted, organ-specific effects?

Molecular modeling studies from Khavinson's group examined 400 possible dipeptide combinations and identified 57 with high selectivity for specific DNA sequences. But these are computational predictions, not experimental demonstrations of binding specificity in living systems.

No independent lab has tested or validated the proposed DNA-binding mechanism.

Key Research Areas and Studies

Lifespan Extension and Tumor Inhibition in Mice (2000)

Khavinson & Anisimov, PMID 10944717 (2000): Vilon (L-Lys-L-Glu) was administered subcutaneously to female CBA mice starting at 6 months of age. The treatment increased physical activity and endurance, decreased body temperature, prolonged lifespan, and inhibited spontaneous tumor growth. Published in Doklady Biological Sciences 372:261–263. No full abstract available on PubMed.

Biological Age and Lifespan in Mice (2000)

Khavinson et al., PMID 11140587 (2000): Vilon's effect on biological age markers and lifespan in mice. Published in Bulletin of Experimental Biology and Medicine 130(7):687–690.

Digestive Enzyme Activity in Rats (2001)

PMID 11586413 (2001): Oral administration of Vilon (Lys-Glu) to male and female Wistar rats aged 3 and 11 months changed activity of digestive enzymes (invertase, maltase, alkaline phosphatase, amino- and dipeptidases) in various portions of the gastrointestinal tract. This study is notable because it demonstrates oral bioactivity of a dipeptide—relevant to the formulation question.

Monocyte/Macrophage Cell Line (2022)

PMC 8999041 (2022): In vitro study in THP-1 monocyte/macrophage cell line. Vilon regulated proliferative activity and inflammatory pathways. Published in International Journal of Molecular Sciences. This is the most recent English-language study specific to Vilon.

Chromatin Remodeling in Aged Lymphocytes (Multiple Studies)

Multiple studies from Khavinson's group (and Georgian collaborators Lezhava et al.) report that Vilon increases IL-2 gene expression in lymphocytes, remodels chromatin structure in aged human cells, and activates nucleolar organizer regions. These are ex vivo studies using lymphocytes from elderly donors—not clinical trials, but they use human tissue.

The Khavinson Evidence Problem

This section addresses the central evidence challenge that applies to Vilon and every compound in the Khavinson bioregulator family. Readers evaluating Vilon cannot assess it without understanding this context.

Single-Lab Dependency

Virtually all published data on Vilon originates from one institutional network: the St. Petersburg Institute of Bioregulation and Gerontology, directed by Vladimir Khavinson until his death in 2024. The Georgian collaborators (Lezhava et al.) who contributed to chromatin studies represent the closest thing to independent replication—but they were direct collaborators, not independent investigators.

No Western lab—at any university, pharmaceutical company, or government research institute—has independently tested Vilon's effects on lifespan, tumor incidence, chromatin structure, or gene expression.

Russian-Language Literature

The bulk of clinical and preclinical data exists in Russian-language journals not indexed on PubMed. The English-language studies accessible to Western readers represent a fraction of the total publication record. This means the full evidence base cannot be audited by readers who do not read Russian.

No Western Regulatory Review

Vilon has never been submitted to the FDA, EMA, TGA, or Health Canada for review. It has no ClinicalTrials.gov entries. The Russian pharmaceutical approvals (for the related tissue extracts Thymalin and Thymogen, not for Vilon itself) were granted under Soviet/Russian regulatory standards that do not meet ICH-GCP requirements.

The Specificity Question

Vilon is Lys-Glu—two of the most abundant amino acids in biology. The claim that this dipeptide achieves organ-specific gene regulation via direct DNA binding, without demonstrated binding specificity in living systems, is the central mechanistic challenge. Computational modeling predicts DNA sequence selectivity, but experimental validation in physiological conditions has not been published.

The Replication Void

In Western pharmacology, a finding does not become established until an independent lab reproduces it. For Vilon, that replication has never occurred. The preclinical data is consistent—but consistency from a single source is not the same as validation from multiple sources.

Claims vs. Evidence

The Human Evidence Landscape

There is no controlled human evidence for Vilon. The compound has never been tested in a randomized, controlled, blinded, or dose-finding trial in humans—in any country, under any regulatory framework.

Ex Vivo Lymphocyte Studies

Multiple studies from Khavinson's group treated lymphocytes extracted from elderly human donors with Vilon in culture, then measured chromatin structure changes. These are human cells, but the peptide was applied in a dish, not administered to a living person. Ex vivo results demonstrate that the peptide can affect human cellular processes in controlled laboratory conditions. They do not demonstrate that the peptide reaches target cells, crosses cell membranes, enters nuclei, or produces measurable immune effects when administered to a human being.

Russian-Language Clinical References

The 2013 review (PMID 24003726) lists Vilon among peptides studied clinically in Russia. The clinical data referenced in that review is published in Russian-language journals not indexed on PubMed and cannot be independently audited in English. The study designs, sample sizes, endpoints, randomization methods, and results are not accessible.

What Would Need to Happen

For human evidence to emerge for Vilon, a research group would need to: 1. Conduct a pharmacokinetic study establishing that the dipeptide is absorbed, reaches target tissues, and enters cells in humans 2. Conduct a dose-finding study establishing tolerable and biologically active doses 3. Conduct a randomized, controlled trial measuring immune function endpoints (not just biomarkers) in a defined population

None of these studies exist or are registered.

Safety, Risks, and Limitations

No Human Safety Data

No formal human safety or toxicology data exists for Vilon in Western-accessible literature. The dipeptide consists of two common amino acids (lysine and glutamic acid), which suggests a favorable safety profile—but "consists of safe building blocks" is not the same as "demonstrated to be safe."

Theoretical Safety Advantage

Ultrashort peptides are generally considered low-risk because they are rapidly degraded by ubiquitous peptidases. A dipeptide of two standard amino acids is unlikely to accumulate, cause immune reactions, or produce off-target receptor effects. This theoretical safety argument is plausible but not validated by formal toxicology studies.

Unknown Pharmacokinetics

The absorption, distribution, metabolism, and excretion (ADME) of Vilon in humans is unknown. How much of an injected or orally administered dipeptide reaches intact cells? How much is degraded before reaching the nucleus? These questions are fundamental and unanswered.

The "It's Just Two Amino Acids" Problem

Lysine and glutamic acid are among the most abundant amino acids in dietary protein. Every meal delivers gram-quantities of these amino acids to the bloodstream. The bioregulator paradigm claims that a dipeptide of these two amino acids, administered in microgram quantities, produces specific biological effects that dietary protein does not. This is not impossible—peptide bonds create structures with properties different from free amino acids—but it is a claim that requires direct pharmacological evidence, which does not exist.

Legal and Regulatory Status

FDA Status

Vilon has never been approved, reviewed, or submitted to the FDA. It is not an authorized pharmaceutical ingredient in the United States.

Russian Status

Vilon itself is not a registered pharmaceutical in Russia. The related thymic preparations Thymalin (tissue extract) and Thymogen (dipeptide Glu-Trp) are registered Russian pharmaceuticals—but they are different compounds. Vilon (Lys-Glu) has no pharmaceutical registration.

WADA Status

Vilon is not specifically listed on the WADA prohibited list. As a synthetic dipeptide, it may fall under S2 (Peptide hormones, growth factors, and related substances) depending on classification—but this is ambiguous for a two-amino-acid molecule with no established hormonal activity.

Market Availability

Vilon is available through research peptide suppliers, typically as lyophilized powder labeled "for research purposes only." Purity, identity, and sterility are not regulated.

Research Protocols and Formulation Considerations

Chemical Composition

Vilon is a synthetic dipeptide: L-Lysyl-L-Glutamic acid. Molecular weight: ~275 Da. Molecular formula: C₁₁H₂₁N₃O₅.

Synthesis

Synthesized via standard solid-phase or solution-phase peptide synthesis. The molecule is small enough that synthesis is trivial by modern peptide chemistry standards.

Stability

As a dipeptide, Vilon is susceptible to rapid degradation by aminopeptidases and dipeptidyl peptidases present throughout biological fluids. Stability in solution is limited. Lyophilized powder is the standard storage form.

Formulation

Research-grade Vilon is typically supplied as lyophilized powder, reconstituted with bacteriostatic water or saline. Some vendors offer capsule formulations intended for oral/sublingual administration.

Dosing in Published Research

Route of Administration

Published animal studies used subcutaneous injection. The rat digestive enzyme study (PMID 11586413) used oral administration, demonstrating that oral bioactivity is at least possible for this dipeptide in rodents.

Doses in Published Studies

Animal studies used doses in the microgram range. Specific doses: PMID 10944717 (mice) — dose not specified in available English abstract. PMID 11586413 (rats) — oral administration, dose not specified in available English abstract.

No human dose has been established by any published study.

Pharmacokinetics

Unknown in humans. The half-life of a free dipeptide in human plasma is expected to be very short (minutes) due to rapid enzymatic degradation by dipeptidyl peptidases.

Dosing in Self-Experimentation Communities

WHY NEARLY EMPTY: Vilon has minimal community adoption compared to mainstream peptides like BPC-157, TB-500, or MK-677. The Khavinson bioregulator market is niche—primarily driven by longevity enthusiasts familiar with Russian peptide science. No systematic community dosing data, dose-response reports, or protocol comparisons exist.

Reported Community Doses

Vendor websites suggest doses in the range of 100–200 mcg/day subcutaneously or sublingually. These doses are not derived from any published dose-finding study. They appear to be extrapolated from Russian supplement protocols and vendor marketing materials.

Frequency and Duration

Community protocols typically suggest cycles of 10–20 days, with rest periods between cycles. This cycling pattern mirrors Russian bioregulator supplement protocols but has no published pharmacological basis.

Combination Stacks

Research into Vilon combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Vilon with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Vilon is a synthetic dipeptide (Lys-Glu) developed by Vladimir Khavinson as part of the bioregulator peptide family—a 50-year research program proposing that ultrashort peptides can modulate gene expression by interacting directly with DNA. It is the simplest molecule in the family and the entry point to Peptidings Cluster S.

The preclinical data tells a consistent story: lifespan extension and tumor inhibition in mice, chromatin remodeling in aged human lymphocytes (ex vivo), and cytokine pathway modulation in vitro. The in vitro and ex vivo work is recent enough (2022) to suggest ongoing interest.

But the evidence limitations are severe. All data comes from one institutional network. No independent lab has replicated any finding. No controlled human trial exists in English-language literature. The proposed DNA-binding mechanism has computational support but no experimental validation in living systems. The founder of the research program died in 2024, and the program's future is uncertain.

Verdict Recapitulation

Vilon earns "Eyes Open" rather than "Thin Ice" because its preclinical portfolio is broader and more consistent than most compounds at this tier. Mouse lifespan data, ex vivo human chromatin evidence, and recent in vitro work represent a more developed preclinical story than a single mechanism study or a single cell-line experiment. But the single-source dependency, the replication void, and the absence of any human clinical data keep it firmly in Tier 4. The Khavinson Evidence Problem—applicable to all nine compounds in this cluster—is the defining limitation.

For readers considering Vilon, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Vilon

Further Reading and Resources

If you want to go deeper on Vilon, the evidence landscape for khavinson bioregulators peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Khavinson Bioregulators Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Vilon — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Khavinson VKh, Anisimov VN. "A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice." Doklady Biological Sciences. 2000;372:261–263. PMID 10944717
2. Khavinson VKh et al. "Effect of vilon on biological age and lifespan in mice." Bulletin of Experimental Biology and Medicine. 2000;130(7):687–690. PMID 11140587
3. "Effect of the dipeptide vilon on activity of digestive enzymes in rats of various ages." Bulletin of Experimental Biology and Medicine. 2001. PMID 11586413
4. Khavinson VKh et al. "Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line." International Journal of Molecular Sciences. 2022;23(8). PMC: 8999041
5. Khavinson VKh, Lezhava TA et al. "Effects of Livagen peptide on chromatin activation in lymphocytes from old people." Bulletin of Experimental Biology and Medicine. 2002;134(4):389–392. PMID 12533768 (Cluster-wide chromatin reference)
6. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies." Advances in Gerontology. 2012;25(4):696–708. PMID 23734519
7. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results." Advances in Gerontology. 2013;26(1):20–37. PMID 24003726

---